“Efficacy and Safety of Risankizumab Compared With Apremilast in Patients With Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s257. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/2404.